The metabolism in primary human hepatocyte cultures often deviates from that in clinical studies, which in turn are hampered by ethical constraints. Here the use of urokinase-type plasminogen activator-severe combined immunodeficiency [uPA(؉/؉)-SCID] mice transplanted with human hepatocytes was investigated as a model for in vivo metabolic studies. The urinary excretion profile after oral administration of 4-androstene-3,17-dione (AD) in chimeric mice was investigated by using gas chromatography-mass spectrometry detection and was compared with previously reported metabolites of AD in humans and cell cultures. Chimeric mice exhibited an AD metabolic profile similar to that of humans, showing androsterone and etiocholanolone as major metabolites. Several hydroxylated steroids were detected as minor metabolites in the chimeric mice compared with hepatocyte cultures. A significant correlation between the extent of liver replacement and the relative abundances of human-type metabolites was established. The results for AD showed that humanized liver uPA-SCID mice can serve as an alternative model for in vivo metabolism studies in humans. In the future, this model could possibly be used for other steroids or pharmaceutical compounds.
The liver is one of the most important organs involved in the metabolism of drugs . Most orally administered steroids are metabolized in the liver and excreted in the urine. The misuse of anabolic androgenic steroids in sports is controlled by evaluating the presence of prohibited substances or their metabolites in urine samples. Because experimental in vivo human excretion studies are not always approved by an ethics committee, the metabolism of steroids is studied mainly in primary human hepatocyte cultures. However, these in vitro experiments do not always accurately predict the in vivo metabolic profile (Schänzer, 1996; Lévesque and Ayotte, 1999; Uralets and Gillette, 1999; Goudreault et al., 2001; Leder et al., 2001; van de Kerkhof, 2001; Lévesque et al., 2002; Brandon et al., 2003; Van Eenoo and Delbeke, 2006) .
In this study a chimeric mouse model with functional human hepatocytes was evaluated as an alternative model for metabolic studies (Gonzalez, 2003; Gonzalez and Yu, 2006) . Urokinasetype plasminogen activator-severe combined immunodeficiency [uPA(ϩ/ϩ)-SCID] mice have a severe transgene-induced liver disease. When transplanted with primary human hepatocytes, up to 90% of the diseased liver parenchyma can be replaced with functional hepatocytes of human origin Meuleman et al., 2005) . The human albumin (hAlb) concentration, measured in the mouse plasma, is a good marker for the replacement index of the chimeric liver.
The expression of human drug-metabolizing enzymes in these chimeric mice has already been investigated (Katoh et al., 2004 (Katoh et al., , 2005a Tateno et al., 2004; Katoh and Yokoi, 2007; Okumura et al., 2007; Emoto et al., 2008; Muruganandan and Sinal, 2008) . Many induction and inhibition reactions typical for human cytochrome P450 enzymes in the liver have been successfully tested in the chimeric mouse. Cytochrome P450 enzymes are predominantly expressed in the liver and play a central role in drug metabolism. Although these experiments demonstrated the activity of human drug-metabolizing enzymes, the complete metabolic excretion profile has not been evaluated yet. The present results indicate the potential of the chimeric mouse as a model for in vivo metabolic studies of designer steroids, for which approval of an ethics committee for administration studies in humans is virtually impossible to obtain.
In the study described herein, a validation of the human-type metabolic profile in chimeric mice with 4-androstene-3,17-dione (AD) as a model steroid was performed. The complete metabolic profile of AD in chimeric mice after oral AD administration has been investigated. The gas chromatography-mass spectrometry (GC-MS) results are compared with data generated from hepatocyte cell cultures and human administration studies (Schänzer, 1996; Lévesque and Ayotte, 1999; Uralets and Gillette, 1999; Goudreault et al., 2001; Leder et al., 2001; van de Kerkhof, 2001; Lévesque et al., 2002; Brandon et al., 2003; Van Eenoo and Delbeke, 2006) .
The endogenous anabolic androgenic steroid AD is a precursor of testosterone (Leder et al., 2001; Lévesque et al., 2002; Van Eenoo and Delbeke, 2006) and is prohibited by the World AntiDoping Agency (The 2009 prohibited list, http://www.wada-ama.org/ rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf). The use of steroids is prohibited in sports because of their performance-enhancing effects. However, most anabolic steroids are produced for therapeutic use. Athletes, aware of the benefits of steroids on weight gain and muscle strength, take them in much higher doses than therapeutically advised. In general, a daily dose of 100 to 300 mg for endogenous steroids is recommended by manufacturers, but higher doses are sometimes used by athletes (Bhasin et al., 1996; Leder et al., 2001) .
In humans, AD is metabolized mainly to androsterone and etiocholanolone (Fig. 1 ). Androsterone and etiocholanolone can be considered as final products in the androgen degradation pathway, whereas testosterone and dihydrotestosterone (DHT) represent inter-FIG. 1. Androstenedione metabolism, indicating which metabolites were found in vivo in humans (1), chimeric mice (2), and nonchimeric mice (3), or in vitro in primary hepatocyte cultures (4). EpiT, epitestosterone; T, testosterone; E, etiocholanolone; A, androsterone; Diol 1, 5␤-androstane-3␣,17␤-diol; Diol 2, 5␣-androstane-3␣,17␤-diol; Diol 3, 5␣-androstane-3␤,17␤-diol; 4OH-AD, 4-hydroxyandrostenedione; 6␣OH-AD, 6␣-hydroxyandrostenedione; 16␣OH-AD, 16␣-hydroxyandrostenedione; 6␤OH-A, 6␤-hydroxyandrosterone; 6␤OH-E, 6␤-hydroxyetiocholanolone; 16␣OH-A, 16␣-hydroxyandrosterone.
mediates. The data obtained in this administration study show that the metabolic profile of AD in chimeric mice closely resembles that in humans.
Materials and Methods
Animals. The project was approved by the Animal Ethics Committee of the Faculty of Medicine of Ghent University (Ghent, Belgium; approval ECD 06/09). uPA(ϩ/ϩ)-SCID mice were transplanted with primary human hepatocytes (chimeric mice), as described previously (Meuleman et al., 2003) . Chimeric mice (n ϭ 6) and nonchimeric mice (n ϭ 4) without transplanted human hepatocytes were used. The nonchimeric mice served as a control group. Before the administration experiments, the hAlb concentration was measured in the mouse plasma. Chimeric mice with different hAlb concentrations were selected in the study (Tables 1 and 2 ). T, testosterone; EpiT, epitestosterone; E, etiocholanolone; A, androsterone; Diol 1, 5␤-androstane-3␣,17␤-diol; Diol 2, 5␣-androstane-3␣,17␤-diol; Diol 3, 5␣-androstane-3␤,17␤-diol. Sample Collection of Mouse Urine. Special metabolic cages for small rodents were purchased from Tecniplast (Someren, The Netherlands). The mice had free access to powdered food and water during the experiments. Because of the design of the metabolic cages, the urine and the feces of the mice were perfectly separated. The urine was collected daily, noninvasively and was stored at Ϫ20°C awaiting analysis.
Study Design. In a pilot study, the detection time in postadministration urine and possible saturation of the metabolic pathways were tested in the mice via oral administration of increasing doses of AD (175, 350, and 600 g). The chimeric and nonchimeric mice were randomly assigned to one of the following groups: administration with 100 l of the placebo or with 100 l of the AD-phosphate-buffered saline (PBS) suspension. The AD-PBS suspension was made by weighing a pure reference standard of AD (Sigma-Aldrich, St. Louis, MO) and afterward dissolving it in 5% ethanol (Biosolve, Valkenswaard, The Netherlands) and further diluting it with PBS (Invitrogen, Merelbeke, Belgium) to reach the final concentration. For the double-blind administration study both the steroid suspension and placebo were administered with a washout period of 72 h between administrations. The placebo was used as an extra control in this study to exclude any stress-related endogenous steroid production.
The steroid suspension or placebo was administered on 3 consecutive days by oral gavage. Urine samples were collected after 24 h on the day before the first administration and on days 1, 2, and 3. The urinary excretion rates per day were measured.
Analysis. GC-MS has proven to be a reliable analytical tool for the identification of AD and its metabolites in mouse urine. The results of the quantitative GC-MS method development and validation with the instrumental settings for GC-MS have been described previously (Lootens et al., 2008) . In brief, mouse urine samples (100 l) containing 17␣-methyltestosterone as an internal standard were hydrolyzed and afterward extracted with 5 ml of diethyl ether (Biosolve). The evaporated organic phase was derivatized and analyzed by GC-MS.
Results
Pilot Study: Dose Selection. After a single oral administration of increasing doses of AD (175, 350, and 600 g) to chimeric mice, the parent compound and several metabolites were detected up to 24 h. No differences in metabolic profile were detected between the 175-and 350-g dose. When 600 g was administered, the relative concentration of the parent drug, AD, increased, indicating possible saturation of the metabolic pathways. Therefore, the ideal administered dose was set at 350 g/gavage. This dose is, per kilogram of body weight, 5 times higher than the normal therapeutic dose used in humans. AD or its metabolites were no longer detected after 24 h; hence multiple dosing (day 1, 2, 3) was possible without interference or accumulative effects. Moreover, a washout period of 72 h was included between the administration of the steroid suspension and placebo.
Blank and Placebo. Before the administration of AD, urine was collected from both nonchimeric and chimeric uPA(ϩ/ϩ)-SCID mice. In both of these groups, the endogenous steroids were undetectable or in the range of the limit of detection (Lootens et al., 2008) . In addition, none of the monitored AD metabolites could be detected in the urine of placebo-treated chimeric and nonchimeric mice. These placebo results indicate that there is no interference of endogenously produced steroids with the detected steroids after AD administration and that the oral gavage did not induce any detectable stress-related steroid production. T, testosterone; EpiT, epitestosterone; E, etiocholanolone; A, androsterone; Diol 1, 5␤-androstane-3␣,17␤-diol; Diol 2, 5␣-androstane-3␣,17␤-diol; Diol 3, 5␣-androstane-3␤,17␤-diol. Administration Results. The urinary metabolite concentrations on days 1, 2, and 3 after multiple AD administration in six chimeric mice and four nonchimeric mice are shown in Tables 1 through 4 . Phase I metabolic reactions and phase II glucuronidation of steroids were checked in the same way as is done for routine doping control analysis (Lootens et al., 2008) . After analyzing the mouse urine samples, the average concentration (n ϭ 3) per steroid and the relative standard deviation (RSD) (percentage) were calculated (Tables 1-4) .
To make the data comparable, the individual metabolite concentrations of Tables 1 through 4 were set relative to the sum of all detected steroids (Figs. 2 and 3) . After AD administration, the metabolic pattern in the nonchimeric control mice was significantly different from that of the chimeric mice. The results for all nonchimeric mice showed similar patterns (Fig. 3) .
Method validation and the low RSD for the intraday measurements indicate good analytical reproducibility (Tables 1-4) . Moreover, an excellent interday repeatability (day 1-day 2-day 3) of the relative abundances of the monitored steroids was observed (Figs. 2 and 3) . Hence, the apparent high interday variation in absolute concentrations of the detected steroids could only be attributed to the uncertainty dmd.aspetjournals.org related to the administered dose. Steroids have a low solubility in polar agents such as PBS, resulting in the formation of a suspension. Nevertheless, gavage of a suspension was still considered to be the best possible option to administer the steroids properly, because other possible administration routes (e.g., mixed with feed) could lead either to contamination problems or to a higher variation in administered dose.
A significant variability in the relative abundances of testosterone and epitestosterone after AD administration between the chimeric mice was noticed (Fig. 2) . A higher epitestosterone than testosterone concentration was found in two chimeric mice (Chim 4 and Chim 6 ). Uncertainty about the origin of epitestosterone still exists in humans (Catlin et al., 2002; Stárka, 2003) , although it is of great interest because it is the denominator in the testosterone to epitestosterone ratio, which is used in sports to monitor misuse of endogenous steroids. Catlin et al. (2002) reported previously that androstenedione administration affects epitestosterone metabolism in men. In this study, AD administration increased epitestosterone excretion in both types of mice and hence the previously reported results were confirmed.
As is commonly known (van de Kerkhof, 2001 ), conversion of AD, a ⌬4 steroid, to a ⌬5 steroid, such as dehydroepiandrosterone (DHEA), does not occur in humans (Fig. 1) . The results for the chimeric and nonchimeric mice are in agreement with these observations, because DHEA was not detected in the mice (Tables 1 and 3) .
Discussion
In humans, the major urinary markers of AD administration are androsterone and etiocholanolone. Testosterone, epitestosterone, DHT, 5␤-androstane-3␣,17␤-diol, 5␣-androstane-3␣,17␤-diol, and 5␣-androstane-3␤,17␤-diol are also described as metabolites (Schän-zer, 1996; Lévesque and Ayotte, 1999; Uralets and Gillette, 1999; Goudreault et al., 2001; Leder et al., 2001; van de Kerkhof, 2001; Catlin et al., 2002; Stárka, 2003; Van Eenoo and Delbeke, 2006) . Although major metabolites in vitro (Lévesque et al., 2002) , 6␣-hydroxyandrostenedione and several other hydroxylated steroids are reported as minor metabolites in vivo (Schänzer, 1996; Lévesque and Ayotte, 1999; Goudreault et al., 2001; van de Kerkhof, 2001; Lévesque et al., 2002; Van Eenoo and Delbeke, 2006) . Therefore, the 16 metabolites monitored in this study were divided into nonhydroxylated and hydroxylated metabolites (Fig. 1) .
In the nonchimeric mice 9 of the 16 screened steroids were detected (Tables 3 and 4) . Within the group of nonhydroxylated metabolites only testosterone, epitestosterone, and AD were detected (Table 3 ; Fig. 1 ). Neither androsterone nor etiocholanolone, the major metabolites reported in humans, nor DHEA, DHT, 5␤-androstane-3␣,17␤-diol, 5␣-androstane-3␣,17␤-diol, and 5␣-androstane-3␤,17␤-diol was detected. On the other hand, most hydroxylated metabolites were found (Table 4 ; Fig. 1 ).
In the chimeric mice, a significant difference could be observed between the results before and after AD administration (Tables 1 and   FIG. 3. Metabolites detected in the 24-h urine after multiple AD administration (day 1-day 2-day 3) to four nonchimeric mice. The mean measured concentrations (n ϭ 3) are set relative to the sum of all steroids ϭ 100%. For abbreviations, see the legend to Fig. 1 . 2). AD is almost completely metabolized, indicating that the metabolic enzymes are sufficiently present, and no saturation occurred. The parameters of the steroid profile that were altered the most were androsterone and etiocholanolone concentrations (Table 1) . Androsterone and etiocholanolone seem to be specific markers for AD use in humans and chimeric mice but not in control nonchimeric mice. Urinary testosterone, epitestosterone, and DHT were also significantly higher in chimeric mice. Based on previous studies investigating AD metabolism in humans (Schänzer, 1996; Lévesque and Ayotte, 1999; Uralets and Gillette, 1999; Goudreault et al., 2001; Leder et al., 2001; van de Kerkhof, 2001; Van Eenoo and Delbeke, 2006) , the same metabolic pathways could be found in the chimeric mice. Both in vivo in humans and in the chimeric mice, androsterone and etiocholanolone are the major metabolites. However, the diols were detected in very low concentrations or even below the limit of quantitation (Table 1) . Figure 4 shows an overview of the relative excreted amounts of hydroxylated and nonhydroxylated steroids for all chimeric and nonchimeric mice. The six chimeric mice are ranked according to their hAlb concentration, showing the effect of the replacement with human hepatocytes on drug metabolism by evaluation of the urinary AD excretion profile (Table 1) . Previously Tateno et al. (2004) showed a positive correlation between the extent of replacement of the liver with human hepatocytes and the hAlb concentration. Hence the increase in nonhydroxylated metabolites in the chimeric mice can be explained by the increased replacement with human hepatocytes. Indeed, a positive correlation (r ϭ 0.82) was found between the plasma hAlb concentration and the relative amount of nonhydroxylated steroids excreted (Fig. 4) . This study confirms that the major human metabolites increase in chimeric mice in an hAlb concentration-dependent manner and lead to a good correlation with human in vivo metabolism.
In the nonchimeric mice the hydroxylated metabolites were most abundant (Fig. 4) . The nonchimeric mice give results similar to the previously described in vitro data, because the same major metabolic pathway (hydroxylation) is described. However, chimeric mice show a high degree of correlation with previously reported in vivo studies of AD. Therefore, this novel chimeric mouse model offers a promising approach, and it is complementary to other models (including in vitro metabolism models).
However, some limitations are involved with the chimeric mouse model. It is technically very challenging to successfully obtain these transplanted mice. Moreover, high-quality cryopreserved human hepatocytes are required to obtain a good success rate for the transplantation procedure . In addition, for other compounds undergoing significant metabolism outside the liver, such as in the small intestine or lungs, the mouse model is less valuable.
In conclusion, this study shows that chimeric mice with a humanized liver can be used for the in vivo study of the human urinary excretion profile of steroids. In contrast to nonchimeric control mice and primary hepatocyte cultures, chimeric mice metabolized orally administered AD in a manner similar to that of humans. However, further research with other known steroids is necessary. Use of the chimeric mouse model circumvents the ethical problems associated with the investigation of steroid metabolism in humans, in whom the detection of designer steroids is still a challenge in doping analysis. In the future this mouse model can potentially be applied to identify and characterize metabolites of designer steroids and nutritional supplements currently abused by athletes. In addition, this chimeric mouse model could be used to study the pharmacokinetics and metabolism of new therapeutic agents.
